Core Laboratories (CLB) EBIT (2022 - 2026)

Core Laboratories has reported EBIT for 5 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 57.28% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.1 million (down 86.93% YoY), and the FY2025 full-year result was $9.6 million, down 83.54% from the prior year.
• EBIT for Q1 2026 stood at $1.9 million, up from -$31.0 million in the prior quarter.
• The five-year high for EBIT was $20.9 million in Q3 2025, with the low at -$31.9 million in Q4 2023.
• Historically, EBIT has averaged $7.5 million across 5 years, with a median of $14.4 million in 2022.
• Annual changes were most pronounced in 2024 — EBIT surged 144.4% — and 2025, when it tumbled 318.7%.
• Core Laboratories' EBIT stood at $15.6 million in 2022, then slumped by 304.38% to -$31.9 million in 2023, then jumped by 144.4% to $14.2 million in 2024, then plunged by 318.7% to -$31.0 million in 2025, then jumped by 106.09% to $1.9 million in 2026.
• The last three EBIT figures came in at $1.9 million (Q1 2026), -$31.0 million (Q4 2025), and $20.9 million (Q3 2025), per Business Quant data.